Welcome to our dedicated page for Esperion Therape SEC filings (Ticker: ESPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Esperion Therapeutics, Inc. (ESPR) SEC filings page provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. Esperion is a commercial-stage biopharmaceutical company listed on the Nasdaq Stock Market LLC under the symbol ESPR, and its filings offer detailed insight into its cardiometabolic and rare/orphan disease business, including oral non-statin LDL-C therapies such as NEXLETOL and NEXLIZET.
Key filing types for Esperion include annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe the company’s business, risk factors, financial statements, and discussion of operations. Current reports on Form 8-K and 8-K/A, several of which are referenced in the provided data, disclose material events such as financial results, underwritten public offerings of common stock, executive appointments, board changes, and other significant corporate developments.
Investors can also review notifications of late filing on Form 12b-25, which explain delays in periodic reports and provide management’s narrative regarding the status of financial closing procedures. For Esperion, these documents have included explanations related to quarterly financial close and corrections to previously furnished earnings releases.
On Stock Titan, Esperion’s filings are updated in near real time as they are made available on EDGAR. AI-powered summaries help explain the content of lengthy documents, highlight key sections, and surface items such as revenue drivers, commercialization plans for NEXLETOL and NEXLIZET, capital-raising transactions, and changes in executive leadership. Users can also identify trading symbol information, exchange listing details, and other disclosures related to Esperion’s common stock directly from these filings.
Esperion Therapeutics (ESPR) reported an insider transaction by its General Counsel. On 10/17/2025, the officer sold 1,248 shares of common stock at $2.6245 per share. The filing states the shares were sold to satisfy tax obligations on vested restricted stock units.
Following the sale, the officer directly owned 392,422 shares. This Form 4 reflects a tax-related sale rather than an open-market disposition for investment purposes.
Esperion Therapeutics, Inc. filed an 8-K reporting a material event that centers on a securities offering. The filing references two press releases dated
Esperion Therapeutics, Inc. is offering 30,000,000 shares of common stock at a public offering price of
Esperion Therapeutics, Inc. is offering additional shares of its common stock on a shelf registration, with the final public offering price to be set at pricing. The company reported a closing Nasdaq price of $3.30 per share on
Esperion Therapeutics, Inc. filed a current report to note that on October 7, 2025 it posted an updated corporate presentation on its investor relations website. The same presentation, dated October 2025, is also provided as Exhibit 99.1 so investors can review the materials directly through the SEC system.
The filing does not introduce new financial statements or disclose specific transaction details. Instead, it formally records that the latest corporate overview and investor slide deck are now publicly available, helping ensure all market participants have equal access to the company’s updated messaging.
Esperion Therapeutics insider transaction: Benjamin Looker, listed as General Counsel and an officer, reported a sale of 6,267 shares of Esperion Therapeutics common stock on 09/17/2025 at a reported price of $2.804 per share. The filing states the shares were sold to satisfy tax obligations on vested restricted stock units. After the sale, Mr. Looker is reported to beneficially own 393,670 shares, held directly. The Form 4 was signed by a power of attorney on 09/18/2025. The report contains no other derivative transactions or additional explanatory disclosures.
Sheldon L. Koenig, President and CEO and Director of Esperion Therapeutics (ESPR), reported a sale and updated holdings. On 09/17/2025 he disposed of 28,427 shares of Esperion common stock at $2.788 per share to satisfy tax obligations on vested restricted stock units. After the reported disposition and recent ESPP purchases, Koenig beneficially owns 1,518,831 shares, which includes 5,770 shares acquired through the company's Employee Stock Purchase Plan. The Form 4 filing is signed 09/18/2025 and reflects that the reporting person is both an officer and a director.
Esperion Therapeutics CFO Benjamin Halladay reported a sale and recent employee-plan purchase on Form 4. On 09/17/2025 he disposed of 7,046 shares of Esperion common stock at a price of $2.808 per share to satisfy tax obligations tied to vested restricted stock units. Following the reported transactions, Mr. Halladay beneficially owns 474,862 shares, which the filing notes includes 7,446 shares recently acquired through Esperion's Employee Stock Purchase Plan. The filing was signed by power of attorney on 09/18/2025.
Esperion Therapeutics (ESPR) report of proposed sale under Rule 144: An individual plans to sell 28,427 common shares through Fidelity Brokerage Services on 09/17/2025, with an aggregate market value of $79,240.27. The shares were acquired on 09/15/2025 via restricted stock vesting and payment was for compensation. The filing lists 201,622,825 shares outstanding, so the proposed sale represents a very small fraction of total shares. The filer also reported a prior sale of 30,474 shares on 06/17/2025 generating $33,792.63. The filing includes the seller's representation regarding material nonpublic information.
Form 144 filed for ESPR insider Benjamin Halladay proposes to sell 7,046 shares of common stock on or about 09/17/2025. The shares were acquired on 09/15/2025 upon restricted stock vesting and are being sold as compensation. The filing lists an aggregate market value of $19,788.69 for the proposed sale versus 201,622,825 shares outstanding, indicating the sale is a very small fraction of the company. The filer previously sold 7,229 shares on 06/17/2025 for $8,329.25 and 11 shares on 07/17/2025 for $12.27. The signer certifies no undisclosed material adverse information.